{"id":343789,"date":"2025-12-14T13:57:02","date_gmt":"2025-12-14T13:57:02","guid":{"rendered":"https:\/\/peraltafinancing.com\/angel-investor\/hidde-ten-brink-nlc\/"},"modified":"2025-12-14T13:57:02","modified_gmt":"2025-12-14T13:57:02","slug":"hidde-ten-brink-nlc","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=343789","title":{"rendered":"Hidde ten Brink & NLC"},"content":{"rendered":"


\n<\/p>\n

\n

We had a chat with Hidde ten Brink, an Investment Director and Lead Venture Finance at <\/span>NLC<\/span><\/a> \u2013 The European Healthtech Venture Builder. By using entrepreneurship at scale, this company\u2019s unique approach allows them to find inventions, and create and support ventures that have the potential to reach and benefit patients all over the world. Find out what\u2019s the greatest success of this Leapfunder alumnus, what are the challenges they\u2019re currently facing and what are their plans for the future.
\"A\"A
<\/span>1. Hi Hidde, thank you for agreeing to do the interview. Could you tell us a bit about NLC<\/a>, how it became the largest Healthtech Venture Builder in Europe, and what led to this idea originally?<\/b><\/p>\n

The idea came from our Founder and CEO, <\/span>Bert Arjan Millenaar<\/span><\/a>. He founded the company in 2015. It started with the observation that 90-95% of the potentially life-saving technology in the healthcare space doesn\u2019t reach the patient. That happens for all kinds of reasons, e.g. there\u2019s no money, no time, no knowledge, no network, etc. Our mission is to bring that number down and ensure that more technology reaches the patients in order to benefit them. Hence the idea of a Venture Builder.<\/span><\/p>\n

At NLC, we source technology throughout Europe. We have a very large network with all the Technology Transfer Offices of the academic hospitals, and a great network of knowledge institutions, where we get a lot of our leads from. We also have an algorithm running on <\/span>PubMed<\/span><\/a>, which is a database for medical publications, as well as an algorithm checking many patent offices We work with a large network of Healthtech corporates, whose technology we also pick up. That\u2019s something that we built up over the years.\u00a0<\/span><\/p>\n

Now we source over 3,500 leads annually. They go into a filtering process where people with in-depth technology and healthcare knowledge try to figure out whether it would be worthwhile to pursue the lead. If we conclude that the technology is potentially impactful for the patient and could be turned into a successful company we try to negotiate a license agreement with the IP holder, which indicates that a company, to be set up by NLC, will have an exclusive licence on the IP and that if we are successful in bringing this company to a point where it\u2019s generating revenue, the IP holder will receive royalties over the revenue. The second thing we do is that we recruit an external CEO to run the company. We have several in-house recruiters who exclusively look for CEOs to run companies. When we\u2019re successful in both previous elements, we set up the company which means we\u2019re the co-founder of the entity and it\u2019s in our portfolio. We very actively support it all the way up to the point that a company has a product to sell and we have been able to sell it to a financial or strategic buyer which can scale it further.<\/span><\/p>\n

2. What do you consider NLC<\/a>\u2019s greatest success and what was the greatest challenge?<\/b><\/p>\n

Our greatest success is that we currently have more than 70 ventures in our portfolio. There are several of them that have reached Technology Readiness Level (TRL) 9 and who have a product in the market, which means they are actually saving lives. For example, <\/span>Nicolab<\/span><\/a> developed an algorithm that helps with a more accurate and faster diagnosis after a stroke by connecting to systems in the hospital where the patient\u2019s CT scan gets sent to the cloud. The algorithm looks at it and quickly gives a very detailed report to a specialist who can then decide what\u2019s the best course of action. They are now in many hospitals nationally and internationally so lives are being saved with the technology that wouldn\u2019t have been there if it wasn\u2019t for NLC. Another example is <\/span>Concord Neonatal<\/span><\/a>, which is a birth trolley that allows for premature babies (as of 24 weeks) to be stabilized close to the mother in a way that the umbilical cord is still intact. That allows oxygen-rich blood to flow from the mother to the baby until it\u2019s stable. That technology is being used in seven countries right now and hundreds of babies have benefited from this product.<\/span><\/p>\n

Our greatest challenge is that we want to become an extremely streamlined and sustainable platform that\u2019s able to build 100 Healthtech ventures annually. We want to get there as quickly and optimally as possible.<\/span><\/p>\n

3. Did you guys ever think of giving up, and what kept you going? What advice would you give a startup founder who is thinking of giving up?<\/b><\/p>\n

At <\/span>NLC<\/span><\/a>, nobody ever thought of giving up because they believed in the mission, the method to achieve it and the model we designed.<\/span><\/p>\n

I would say being an entrepreneur means you will face a lot of setbacks and that\u2019s what we deal with at NLC all the time as well. We\u2019re in the very early stage which means a lot of things fail, but that\u2019s just part of the game. You need to be mentally able to deal with that and not be thrown back every time you encounter a setback. You need to be strong enough to keep going but also wise enough to recognize when it\u2019s a good time to give up if the ideas you\u2019re working on simply won\u2019t work.<\/span><\/p>\n

4. What advice would you give a startup founder who is raising his first funding?<\/b><\/p>\n

I lead a team that\u2019s responsible for getting funding for our portfolio ventures, so I\u2019m involved with fundraising all the time. The main advice that I have is to be prepared. You\u2019re asking people to invest money in your company, but they\u2019re also investing in you as a person. You really need to be able to gain the trust of the investors, and they need to feel that their money is safe with you. You need to make sure that you come across as reliable, detailed, flexible, sharp, well-prepared, and well-thought-through. Once you start approaching investors, your story needs to be completely solid and it needs to look good as well. If your pitch deck looks sloppy, investors are going to think there are mistakes everywhere and they won\u2019t be able to trust you with their money. The old cliche \u201cyou only get one chance to make a first impression\u201d is certainly true when it comes to investors.<\/span><\/p>\n

5. What role did Leapfunder<\/a> play in NLC\u2019s journey? What is the future of NLC<\/a>?<\/b><\/p>\n

The funding round we had on Leapfunder was of instrumental importance to the future of NLC because it kickstarted the whole operation and ultimately led to the organisation that we are today. The other aspect is that it also started to build our network. We are very dependent on our network because we do entrepreneurship at scale. To do that well we need a great network; we need to connect everybody at NLC but also our ventures to many different types of people, from medical specialists to investors.<\/span><\/p>\n

As for the future of NLC, we\u2019re focusing on three elements, one is continued production \u2013 our target for this year is 22 new ventures. One fund that we\u2019re currently raising is <\/span>Elithia<\/span><\/a>, a specialized BioTech fund aimed to fund 22 early-stage BioTech projects over the next few years. We\u2019re actively fundraising for that and we have quite a few commitments already.\u00a0<\/span><\/p>\n

Another big game-changer for NLC will be our new fund, the NLC Health Impact Fund. It will be EUR 100 million large and aimed at larger investors. The goal is to close that in Q1-Q2 next year. It will allow for a lot more funding to go to our ventures.<\/span><\/p>\n

Lastly, we\u2019re actively looking for technology in the <\/span>Green Health space<\/span><\/a> which we can pick up and turn into a venture. NLC has the potential, vision and energy to become an even larger force in the European Healthtech innovation.<\/span><\/p>\n

Thanks for sharing your story and insights, Hidde. We wish you and NLC the best of luck in your future endeavours.<\/span><\/p>\n

Join our network of startups & investors!<\/span><\/p>\n

\t\t\t\t<\/div>\n\n","protected":false},"excerpt":{"rendered":"

We had a chat with Hidde ten Brink, an Investment Director and Lead Venture Finance at NLC \u2013 The European Healthtech Venture Builder. By using entrepreneurship at scale, this company\u2019s unique approach allows them to find inventions, and create and support ventures that have the potential to reach and benefit patients all over the world. […]<\/p>\n","protected":false},"author":1,"featured_media":343790,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12034],"tags":[166920,16095,166921,166922,166923,597,166924,166931,166925,166926,166927,166932,166928,166929,3862,19182,166930],"dealstore":[],"offerexpiration":[],"class_list":["post-343789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-angel-investor","tag-bert-arjan-millenaar","tag-brink","tag-concord-neonatal","tag-elithia","tag-green-health-space","tag-health","tag-healthtech","tag-hidde","tag-hidde-ten-brink","tag-leapfunder-alumnus","tag-nicolab","tag-nlc","tag-nlc-the-european-healthtech-venture-builder","tag-pubmed","tag-ten","tag-the-netherlands","tag-venture-builder"],"yoast_head":"\nHidde ten Brink & NLC - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=343789\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hidde ten Brink & NLC - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"We had a chat with Hidde ten Brink, an Investment Director and Lead Venture Finance at NLC \u2013 The European Healthtech Venture Builder. By using entrepreneurship at scale, this company\u2019s unique approach allows them to find inventions, and create and support ventures that have the potential to reach and benefit patients all over the world. […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=343789\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-14T13:57:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=343789#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=343789\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"Hidde ten Brink & NLC\",\"datePublished\":\"2025-12-14T13:57:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=343789\"},\"wordCount\":1369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=343789#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png\",\"keywords\":[\"Bert Arjan Millenaar\",\"Brink\",\"Concord Neonatal\",\"Elithia\",\"Green Health space\",\"Health\",\"HealthTech\",\"Hidde\",\"Hidde ten Brink\",\"Leapfunder alumnus\",\"Nicolab\",\"NLC\",\"NLC - The European Healthtech Venture Builder\",\"PubMed\",\"Ten\",\"The Netherlands\",\"venture builder\"],\"articleSection\":[\"Angel Investor\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=343789#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=343789\",\"url\":\"https:\/\/fivemor.com\/?p=343789\",\"name\":\"Hidde ten Brink & NLC - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=343789#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=343789#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png\",\"datePublished\":\"2025-12-14T13:57:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=343789#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=343789\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/?p=343789#primaryimage\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png\",\"width\":1000,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=343789#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hidde ten Brink & NLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hidde ten Brink & NLC - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=343789","og_locale":"en_US","og_type":"article","og_title":"Hidde ten Brink & NLC - Som2ny Network","og_description":"We had a chat with Hidde ten Brink, an Investment Director and Lead Venture Finance at NLC \u2013 The European Healthtech Venture Builder. By using entrepreneurship at scale, this company\u2019s unique approach allows them to find inventions, and create and support ventures that have the potential to reach and benefit patients all over the world. […]","og_url":"https:\/\/fivemor.com\/?p=343789","og_site_name":"Som2ny Network","article_published_time":"2025-12-14T13:57:02+00:00","og_image":[{"width":1000,"height":500,"url":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=343789#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=343789"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"Hidde ten Brink & NLC","datePublished":"2025-12-14T13:57:02+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=343789"},"wordCount":1369,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"image":{"@id":"https:\/\/fivemor.com\/?p=343789#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png","keywords":["Bert Arjan Millenaar","Brink","Concord Neonatal","Elithia","Green Health space","Health","HealthTech","Hidde","Hidde ten Brink","Leapfunder alumnus","Nicolab","NLC","NLC - The European Healthtech Venture Builder","PubMed","Ten","The Netherlands","venture builder"],"articleSection":["Angel Investor"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=343789#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=343789","url":"https:\/\/fivemor.com\/?p=343789","name":"Hidde ten Brink & NLC - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fivemor.com\/?p=343789#primaryimage"},"image":{"@id":"https:\/\/fivemor.com\/?p=343789#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png","datePublished":"2025-12-14T13:57:02+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=343789#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=343789"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/?p=343789#primaryimage","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/12\/Hidde-ten-Brink-NLC-The-European-Healthtech-Venture-Builder-1.png","width":1000,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=343789#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"Hidde ten Brink & NLC"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/343789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=343789"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/343789\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/media\/343790"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=343789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=343789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=343789"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=343789"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=343789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}